In patients with CKD presenting with hyperkalemia where up-titration of RAAS blockade may be prohibited, SGLT2 inhibitors may enhance kaliuresis by increasing distal delivery of sodium and stimulating aldosterone, thereby reducing hyperkalemia (Yau et al., 2022). The gene discussed is SLC5A2; the disease is Hyperkalemia.